{"id":"W2793364080","doi":"10.1001/jamaoncol.2018.0013","title":"Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer","year":2018,"lang":"en","type":"letter","venue":"JAMA Oncology","topic":"Gastric Cancer Management and Outcomes","field":"Medicine","cited_by":1812,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"Genentech; Daiichi Sankyo Europe; Gilead Sciences; National Cancer Institute; Sirtex Medical; Five Prime Therapeutics; Ipsen; Eli Lilly and Company; Ono Pharmaceutical; Astellas Pharma; Yakult Honsha; Sanofi; Kyowa Hakko Kirin; MacroGenics; Arog Pharmaceuticals; Pfizer; Incyte; Halozyme; Amgen; Celgene; Bristol-Myers Squibb; AstraZeneca; Chugai Pharmaceutical; Agios Pharmaceuticals","keywords":"Medicine; Pembrolizumab; Internal medicine; Cancer; Cohort; Response Evaluation Criteria in Solid Tumors; Progressive disease; Clinical endpoint; Gastroenterology; Surgery; Disease; Immunotherapy; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.008114240074526269,"score_gpt":0.2647737009068763,"score_spread":0.25665946083235,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}